stock options

Getty Copper appoints Ryan O'Regan as CEO and Dr. Roy Greig as VP Exploration, grants 22.45M stock options, and hires marketing firms to boost investor awareness.

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.

Cytokinetics granted inducement stock options and RSUs to five new employees hired in early 2026, using Nasdaq listing rule 5635(c)(4) to compensate talent.

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.

Elutia grants 460,000 non-qualified stock options to three new employees at $1.09 exercise price with four-year vesting under Nasdaq inducement rules.

Cytokinetics insider Andrew Callos sold $929K in stock options weeks after FDA approval of heart drug myqorzo, reducing holdings by 23%.

Tango Therapeutics grants new employee 367,500 stock options and 60,000 RSUs valued at $11.94 exercise price under inducement plan.

Pacira BioSciences awarded stock options and RSUs to three new employees totaling 7,900 shares at $22.10 exercise price under its inducement plan.

Trade Desk CEO Jeffrey Green purchased $148M in stock at $22.93-$25.25, driving 9.25% after-hours rally despite 62.77% annual decline.

Kaspi.kz shareholders to vote April 15, 2026 on 850 KZT dividend per share, 2025 financials approval, and Deloitte auditor renewal.

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.